The Latest

Tirbanibulin Ointment 1% as a Novel Treatment for Actinic Keratosis: Phase 1 and 2 Results

By December 17, 2020No Comments

Featured Article

Featured Article

Current field-directed treatments of actinic keratosis (AK), a pre-malignant condition, are often limited by severe local reactions and/or complex treatment. Tirbanibulin, a novel potent anti-proliferative synthetic agent that inhibits tubulin polymerization and Src kinase signalling, is being developed as a convenient, safe, and effective field treatment of actinic keratosis.

Read more

Current field-directed treatments of actinic keratosis (AK), a pre-malignant condition, are often limited by severe local reactions and/or complex treatment. Tirbanibulin, a novel potent anti-proliferative synthetic agent that inhibits tubulin polymerization and Src kinase signalling, is being developed as a convenient, safe, and effective field treatment of actinic keratosis.

Steven Kempers MD, Janet DuBois MD, Seth Forman MD, Amy Poon BS MA, Eva Cutler BS BA, Hui Wang PhD, David Cutler MD FRCP(C), Jane Fang MD, Rudolf Kwan MBBS MRCP

 

Actinic keratosis (AK) is a pre-malignant condition, associated with prolonged ultraviolet damage predominantly on the face/scalp, trunk, and extremities. AK affects ~58 million individuals in the US, and typically occurs in males, fair-skinned individuals, and those of advancing age. As the progression of AK to invasive squamous cell carcinoma (iSCC) is unpredictable, the generally accepted approach is to treat all AK.

Current treatments are lesion- or field-directed therapies. Lesion-directed therapies are used when the lesion burden is low; but these modalities can cause scarring and long-term pigmentary changes. Field-directed therapies are used to treat multiple lesions, large areas, and subclinical lesions.

Commonly used topical treatments, while effective, frequently cause moderate-to-severe application-site reactions and deleterious effects on uninvolved skin, which are often considered unacceptable to patients. Moreover, many of these treatments have lengthy or cumbersome dosing regimens that may undermine treatment compliance and compromise efficacy.

Given the disadvantages of available topical therapies, there is a need to develop an agent that has low potential for severe local reactions, effective AK clearance, and convenient dosing.

Read Full Article Now
Article Cited in this Post

You May Also Like

WATCH VIDEO ABSTRACT: Scarring and Dyschromias in Fitzpatrick Skin Type IV-VI: A Review of Dermatologic Treatment Protocols

| Featured Articles, JDD Highlights, The Latest | No Comments
Click Here to View Video Abstract Importance: Managing chronic conditions is an essential aspect of dermatologic care, especially regarding the resolution of inflammatory dermatologic disease and recovery of skin lesions. Short-term…

WATCH VIDEO ABSTRACT: Assessing Implicit Bias in Dermatology

| Featured Articles, JDD Highlights, JDD in the Media, The Latest | No Comments
Click Here to Watch Video Abstract   Background: Patients with skin of color (SOC), defined as Fitzpatrick skin types IV to VI, and of varying ethnicities are under-represented in dermatology. This…

JDD in the News: Increased Dose of Adalimumab in Overweight, Obese Patients; Topical for Infantile Hemangiomas

| Featured Articles, JDD Highlights, JDD in the Media, The Latest | No Comments
Healio covered a JDD study on the impact of an increased dose of adalimumab in hidradenitis suppurativa patients who are overweight or obese. Researchers from the University of California San…

Leave a Reply